GlobalData on MSN2d
Novo Nordisk’s haemophilia A drug stops bleeds in 74% of children
Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...
FierceBiotech3d
Novo Nordisk adds pediatric data to bulging bag of evidence on near-approval hemophilia A prospect
Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...
PMLiVE2d
Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study
Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in ...
BioSpace2d
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...
Yahoo Finance3d
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis ... 7 February 2025 – Novo Nordisk today announced interim results ...
Novo Nordisk reports interim results from late-stage trial of its haemophilia A treatment
Novo Nordisk announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia ...
The Pharma Letter2d
Novo Nordisk adds to Mim8 data set ahead of filing
Danish pharma major Novo Nordisk has announced interim results from the Phase III FRONTIER3 trial of 70 children with ...
Yahoo Finance2d
Novo Nordisk’s haemophilia A drug stops bleeds in 74% of children
Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The FRONTIER3 trial (NCT05306418) achieved its co-primary endpoints ...
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds Bagsværd, Denmark, 7 February 2025 – Novo ...